381 related articles for article (PubMed ID: 24316730)
1. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Nicolussi A; D'Inzeo S; Mincione G; Buffone A; Di Marcantonio MC; Cotellese R; Cichella A; Capalbo C; Di Gioia C; Nardi F; Giannini G; Coppa A
Int J Oncol; 2014 Feb; 44(2):548-56. PubMed ID: 24316730
[TBL] [Abstract][Full Text] [Related]
2. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation.
Franzoni A; Dima M; D'Agostino M; Puppin C; Fabbro D; Loreto CD; Pandolfi M; Puxeddu E; Moretti S; Celano M; Bruno R; Filetti S; Russo D; Damante G
Thyroid; 2009 Mar; 19(3):247-55. PubMed ID: 19207009
[TBL] [Abstract][Full Text] [Related]
3. BRAF(V600E) mutation and the biology of papillary thyroid cancer.
Frasca F; Nucera C; Pellegriti G; Gangemi P; Attard M; Stella M; Loda M; Vella V; Giordano C; Trimarchi F; Mazzon E; Belfiore A; Vigneri R
Endocr Relat Cancer; 2008 Mar; 15(1):191-205. PubMed ID: 18310287
[TBL] [Abstract][Full Text] [Related]
4. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
5. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
6. [Expression of BRAF V600E mutation in different thyroid lesions].
Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
[TBL] [Abstract][Full Text] [Related]
7. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
8. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
[TBL] [Abstract][Full Text] [Related]
9. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
10. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
11. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
12. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
[TBL] [Abstract][Full Text] [Related]
13. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR.
Jeong D; Jeong Y; Park JH; Han SW; Kim SY; Kim YJ; Kim SJ; Hwangbo Y; Park S; Cho HD; Oh MH; Yang SH; Kim CJ
Ann Surg Oncol; 2013 Mar; 20(3):759-66. PubMed ID: 23179992
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.
Atik E; Guray M; Gunesacar R; Ozgur T; Canda T
Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099
[TBL] [Abstract][Full Text] [Related]
15. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
[TBL] [Abstract][Full Text] [Related]
16. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
17. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
[TBL] [Abstract][Full Text] [Related]
18. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
[TBL] [Abstract][Full Text] [Related]
19. BRAF(V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas.
Durante C; Tallini G; Puxeddu E; Sponziello M; Moretti S; Ligorio C; Cavaliere A; Rhoden KJ; Verrienti A; Maranghi M; Giacomelli L; Russo D; Filetti S
Eur J Endocrinol; 2011 Sep; 165(3):455-63. PubMed ID: 21653734
[TBL] [Abstract][Full Text] [Related]
20. Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.
Gandolfi G; Sancisi V; Torricelli F; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A
J Clin Endocrinol Metab; 2013 May; 98(5):E934-42. PubMed ID: 23533235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
